• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.

    7/17/26 3:27:57 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    Nuvalent, Inc.

    (Name of Issuer)


    Class A common stock, $0.0001 par value per share

    (Title of Class of Securities)




    670703107

    (CUSIP Number)
    07/15/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Management Company, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Mgmt IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Private Design Fund IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Mgmt HIF, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Healthcare Innovations Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Mgmt, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    Deerfield Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    670703107


    1Names of Reporting Persons

    James E. Flynn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nuvalent, Inc.
    (b)Address of issuer's principal executive offices:

    One Broadway, 14th Floor, Cambridge, Massachusetts 02142
    Item 2. 
    (a)Name of person filing:

    James E. Flynn, Deerfield Management Company, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt, L.P. and Deerfield Partners, L.P.
    (b)Address or principal business office or, if none, residence:

    James E. Flynn, Deerfield Management Company, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt, L.P. and Deerfield Partners, L.P. 345 Park Avenue South, 12th Floor, New York, NY 10010
    (c)Citizenship:

    Deerfield Management Company, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt HIF, L.P and Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
    (d)Title of class of securities:

    Class A common stock, $0.0001 par value per share
    (e)CUSIP No.:

    670703107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Deerfield Management Company, L.P. - 0 shares Deerfield Mgmt IV, L.P. - 0 shares Deerfield Mgmt HIF, L.P. - 0 shares Deerfield Mgmt, L.P. - 0 shares Deerfield Healthcare Innovations Fund, L.P. - 0 shares Deerfield Private Design Fund IV, L.P. - 0 shares Deerfield Partners, L.P. - 0 shares James E. Flynn - 0 shares
    (b)Percent of class:

    Deerfield Management Company, L.P. - 0.0% Deerfield Mgmt IV, L.P. - 0.0% Deerfield Mgmt HIF, L.P. - 0.0% Deerfield Mgmt, L.P. - 0.0% Deerfield Healthcare Innovations Fund, L.P. - 0.0% Deerfield Private Design Fund IV, L.P. - 0.0% Deerfield Partners, L.P. - 0.0% James E. Flynn - 0.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    All Reporting Persons - 0

     (ii) Shared power to vote or to direct the vote:

    Deerfield Management Company, L.P. - 0 Deerfield Mgmt IV, L.P. - 0 Deerfield Private Design Fund IV, L.P. - 0 Deerfield Mgmt HIF, L.P. - 0 Deerfield Healthcare Innovations Fund, L.P. - 0 Deerfield Mgmt, L.P. - 0 shares Deerfield Partners, L.P. - 0 shares James E. Flynn - 0

     (iii) Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Deerfield Management Company, L.P. - 0 Deerfield Mgmt IV, L.P. - 0 Deerfield Private Design Fund IV, L.P. - 0 Deerfield Mgmt HIF, L.P. - 0 Deerfield Healthcare Innovations Fund, L.P. - 0 Deerfield Mgmt, L.P. - 0 shares Deerfield Partners, L.P. - 0 shares James E. Flynn - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deerfield Management Company, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Mgmt IV, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Private Design Fund IV, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Mgmt HIF, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Healthcare Innovations Fund, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Mgmt, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    Deerfield Partners, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
     
    James E. Flynn
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:07/17/2026
    Exhibit Information

    Exhibit List Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

    Get the next $NUVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    6/24/2026$124.00Outperform → Mkt Perform
    Bernstein
    5/22/2026$189.00Outperform
    Bernstein
    3/30/2026$116.00Overweight
    Wells Fargo
    11/24/2025Buy
    Truist
    11/12/2025$126.00Buy
    Canaccord Genuity
    10/16/2025$115.00Buy
    Stifel
    10/15/2025$135.00Overweight
    Cantor Fitzgerald
    9/4/2025$122.00Buy
    Guggenheim
    More analyst ratings

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director by Deputization Flynn James E returned $427,056 worth of Class A Common Stock - Restricted Stock Units to the company (3,444 units at $124.00) and returned $2,138,807,800 worth of shares to the company (17,248,450 units at $124.00) (SEC Form 4) to satisfy withholding tax

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    7/17/26 3:27:17 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meyers Michael L. returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    7/15/26 7:11:31 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Balcom Alexandra returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    7/15/26 7:11:06 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.

    SCHEDULE 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    7/17/26 3:27:57 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Nuvalent Inc.

    25-NSE - Nuvalent, Inc. (0001861560) (Subject)

    7/15/26 9:32:36 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Nuvalent Inc.

    POSASR - Nuvalent, Inc. (0001861560) (Filer)

    7/15/26 9:22:59 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nuvalent downgraded by Bernstein with a new price target

    Bernstein downgraded Nuvalent from Outperform to Mkt Perform and set a new price target of $124.00

    6/24/26 8:38:37 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Nuvalent with a new price target

    Bernstein initiated coverage of Nuvalent with a rating of Outperform and set a new price target of $189.00

    5/22/26 9:02:44 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Nuvalent with a new price target

    Wells Fargo initiated coverage of Nuvalent with a rating of Overweight and set a new price target of $116.00

    3/30/26 8:25:33 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

    DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research an

    6/9/26 9:44:01 AM ET
    $GSK
    $NUVL
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

    New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra

    5/27/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

    Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trialTKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-naïve patients with advanced ALK-positive NSCLCFirst presentation of encouraging preliminary data for zidesamtinib in patients with advanced ROS1-positive solid tumors other than NSCLC from ARROS-1 trialCAMBRIDGE, Mass., May 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highli

    5/21/26 5:23:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:50:28 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:34:36 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    5/15/24 6:39:30 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Financials

    Live finance-specific insights

    View All

    Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

    In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectivelyNeladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing designCompany p

    11/17/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

    Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.

    11/14/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

    Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmarkIn the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of respo

    6/24/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

    New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra

    5/27/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

    Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

    8/7/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care